AC
ARCT icon

AXQ Capital’s Arcturus Therapeutics ARCT Stock Holding History

AXQ Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$177K Sell
22,982
-5,686
-20% -$41.5K 0.02% 777
2025
Q4 		$176K Buy
+28,668
New +$310K 0.04% 594

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AXQ Capital's ARCT Position: Q1 2026 in Review

AXQ Capital reduced its Arcturus Therapeutics (ARCT) stake by 20% in Q1 2026, selling an estimated $41.5K and leaving 22,982 shares worth $177K. The position accounts for 0.02% of the portfolio, ranked #777.

AXQ Capital first reported a position in ARCT in Q4 2025 and has held it in 2 quarters since. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • AXQ Capital held 22,982 shares of Arcturus Therapeutics worth $177K as of Q1 2026.
  • AXQ Capital sold 5,686 Arcturus Therapeutics shares in Q1 2026, an estimated $41.5K.
  • Arcturus Therapeutics made up 0.02% of AXQ Capital's portfolio in Q1 2026, its #777 holding.
  • AXQ Capital first reported a position in Arcturus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.